Tectonic Therapeutic, Inc.
Clinical Trials
2
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
- Conditions
- Pulmonary HypertensionHeart Failure With Preserved Ejection Fraction
- Interventions
- Drug: PlaceboDrug: TX000045- Dose ADrug: TX000045- Dose B
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Tectonic Therapeutic
- Target Recruit Count
- 180
- Registration Number
- NCT06616974
- Locations
- 🇺🇸
Scottsdale, Scottsdale, Arizona, United States
🇺🇸San Francisco, San Francisco, California, United States
🇺🇸Jacksonville, Jacksonville, Florida, United States
News
Tectonic's TX45 Shows Promise for Pulmonary Hypertension Treatment, Receives Analyst Upgrade
Leerink Partners analyst David Risinger raises Tectonic Therapeutic's price target to $118, citing TX45's potential as a best-in-class treatment for PH-HFpEF.
Tectonic's TX45 Shows Promise in Phase 1b Trial for Pulmonary Hypertension with HFpEF
Tectonic Therapeutic's TX45 demonstrated significant improvements in left ventricular function and pulmonary hemodynamics in patients with PH-HFpEF.
Tectonic Therapeutic's TX45 Shows Promise in Phase Ia Trial for Pulmonary Hypertension
Tectonic Therapeutic reported positive topline data from its Phase Ia trial of TX45 for Group 2 pulmonary hypertension with preserved ejection fraction (PH-HFpEF).